Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT07419321

Social Isolation and Aging in Schizophrenia

Social Isolation and Aging in Schizophrenia — Recruiting • Respiratory / COPD / Asthma • NCT07419321.

📅 25 Mar 2026 ⏱ 4 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07419321
Sponsor
Icahn School of Medicine at Mount Sinai
Start
2024-01-09
ClinicaliQ Trial Snapshot
  • Social Isolation and Aging in Schizophrenia — Recruiting • Respiratory / COPD / Asthma • NCT07419321.
  • Individuals diagnosed with schizophrenia and related psychotic disorders (SZ) exhibit a markedly elevated risk of premature mortality, with a 10-20-year shorter lifespan relative to the general population. Increased mortality rates in SZ are largely attributable to the early manifestation of medical conditions….
  • Sponsor: Icahn School of Medicine at Mount Sinai.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Individuals diagnosed with schizophrenia and related psychotic disorders (SZ) exhibit a markedly elevated risk of premature mortality, with a 10-20-year shorter lifespan relative to the general population. Increased mortality rates in SZ are largely attributable to the early manifestation of medical conditions that normally occur later in life, a process known as 'accelerated aging'. While unhealthy lifestyle behaviors, such as smoking and unhealthy diet, account, in part, for accelerated aging in SZ, the excess of physical comorbidities cannot be solely attributed to these factors. Remarkably, the direct adverse health effects…

Eligibility Snapshot
  • Inclusion and

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment
Respiratory / COPD / Asthma · 02 Apr 2026
Digital spirometry algorithms can improve diagnostic accuracy for asthma and COPD in primary care and community diagnostic centres, potentially reducing unnecessary referrals…
View guideline →
Clinical Brief
‘My baby scratches and scratches’: Families say their homes are making their children sick
Respiratory / COPD / Asthma · BBC Health · 23 Apr 2026
Temporary housing conditions are contributing to increased rates of childhood skin conditions (notably atopic dermatitis), with families reporting persistent scratching and distress…
View brief →
Guideline
Digital technologies to support self-management of asthma: early-use assessment
Respiratory / COPD / Asthma · 05 May 2026
Use digital asthma self-management tools (apps, web platforms, wearables) as adjuncts to standard care to help patients monitor symptoms, track triggers, and…
View guideline →
Guideline
GINA 2024 Report: Global Strategy for Asthma Management and Prevention
Respiratory / COPD / Asthma · 31 Mar 2026
GINA 2024 reinforces no SABA-only treatment for any asthma severity: all patients should receive ICS-containing controller therapy or ICS-formoterol MART as first-line…
View guideline →
Clinical Brief
Abrysvo▼ (Pfizer RSV vaccine) and Arexvy▼ (GSK RSV vaccine): be alert to a small risk of Guillain-Barré syndrome following vaccination in older adults
Infectious Disease · MHRA · 07 Jul 2025
There is a small increase in the risk of Guillain-Barré syndrome following vaccination with Abrysvo (Pfizer respiratory syncytial virus (RSV) vaccine) and…
View brief →
Clinical Brief
Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines
Respiratory / COPD / Asthma · MHRA · 24 Apr 2025
Healthcare professionals and patients are reminded of the risk of severe asthma attacks and increased mortality associated with overuse of SABA with…
View brief →